TY - JOUR
T1 - A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk
AU - Wakefield, Claire E.
AU - Meiser, Bettina
AU - Homewood, Judi
AU - Peate, Michelle
AU - Taylor, Alan
AU - Lobb, Elizabeth
AU - Kirk, Judy
AU - Young, Mary-Anne
AU - Williams, Rachel
AU - Dudding, Tracy
AU - Tucker, Kathy
AU - Barlow-Stewart, K.
AU - Fenton, G.
AU - Goodwin, A.
AU - Zodgekar, P.
AU - Andrews, L.
AU - Koeler, J.
AU - Overkov, A.
AU - Tyler, J.
AU - Warner, B.
AU - Gleeson, M.
AU - Groombridge, C.
AU - O'Donnell, S.
AU - Spigelman, A.
AU - McMahon, C.
AU - Hossack, L.
AU - Kentwell, M.
AU - Aragona, C.
AU - D'Souza, R.
AU - Gaff, C.
AU - Hodgkin, L.
AU - Ward, R.
AU - Butow, P.
AU - Davey, H.
AU - the Australian GENetic testing Decision Aid Collaborative Group
PY - 2008/1
Y1 - 2008/1
N2 - Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ 2(2) = 6.82; P = 0.033; χ 2(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ 2(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ 2(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.
AB - Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ 2(2) = 6.82; P = 0.033; χ 2(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ 2(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ 2(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.
KW - Decision aid
KW - Genetic testing
KW - Hereditary breast cancer
KW - Hereditary ovarian cancer
KW - Patient education
UR - http://www.scopus.com/inward/record.url?scp=37249025159&partnerID=8YFLogxK
U2 - 10.1007/s10549-007-9539-2
DO - 10.1007/s10549-007-9539-2
M3 - Article
C2 - 17333332
AN - SCOPUS:37249025159
SN - 0167-6806
VL - 107
SP - 289
EP - 301
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -
